医学
恶性肿瘤
癌症
免疫疗法
腺癌
肿瘤科
食管癌
阶段(地层学)
内科学
基底细胞
病理
生物
古生物学
作者
Kazuto Harada,Jane Elizabeth Rogers,Masaaki Iwatsuki,Kohei Yamashita,Hideo Baba,Jaffer A. Ajani
出处
期刊:F1000Research
[Faculty of 1000]
日期:2020-10-01
卷期号:9: 1189-1189
被引量:143
标识
DOI:10.12688/f1000research.22926.1
摘要
Esophageal cancer (EC) is an aggressive malignancy with an increasing incidence and a poor prognosis. EC is histologically divided into two major categories: adenocarcinoma (EAC) and squamous cell carcinoma (ESCC). EAC and ESCC are molecularly different and therefore treatments should reflect the respective histological subtype. Combined modality therapy is needed for localized EC. When EC is advanced (stage 4), systemic therapy is the mainstay treatment for palliation. For localized EC, several strategies are considered standard, and more trials are necessary to determine a unified and more effective approach. The management for advanced EC is slowly evolving as immunotherapy is showing some promise for ESCC, but more data from ongoing studies are anticipated. Treatment advances will be based on high-definition genomic investigation of individual tumors. Herein, we review the contemporary trends in diagnosing and treating EAC and ESCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI